CURRICULUM VITAE - Department of Pharmacy

Personal Particulars
Name: HO Han Kiat
Address: Block S4, #03-03
18 Science Drive 4
Singapore 117543
Tel: 65-65167963
CURRICULUM VITAE
HO HAN KIAT
Email: phahohk@nus.edu.sg
Job Title: Assistant Professor, Department of Pharmacy, NUS
Secondary: Adjunct Investigator, IMB, A*STAR
Education and Qualification
July 1996 to May 2000: BSc.(Pharmacy) 1 st Class Honors
1
Ho Han Kiat
Updated: January 2013
Sep 2000 to Oct 2005: Ph.D. (Medicinal Chemistry), University of
Washington, USA

Scholarships and Awards
1999: Lee Kuan Yew Gold Medal
1999: Chalmers Medal
1996-1999: Five times recipient of Dean’s List award
1999: Glaxo Wellcome Overseas Training Scheme
2
Ho Han Kiat
Updated: January 2013
2000-2005: Overseas Graduate Scholarship with the Agency for
Science, Technology and Research (A*STAR)
2004: Merck Award/scholarship (Dept of Medicinal Chemistry, Univ
of Washington)
2005: Carl Smith Award- Honorable mention
2009-2012: Three-time recipient of Faculty Teaching Excellence Award
2009-2012: Two-time recipient of Annual Teaching Excellence Award
Professional Experiences:
May 2000-Aug 2000: Research assistant at the Department of Pharmacy,
National University of Singapore.
Fall 2001: Teaching assistant for Medicinal Chemistry course
for pharmacy students (MEDCH 402, Medicinal
chemistry of anticancer agents and vitamins).
Spring 2003: Teaching assistant for Medicinal Chemistry course
for pharmacy students (MEDCH 401, Immunizing and
antimicrobial agents)
Dec 2005-present: Research fellowship at the Institute of Medical
Biology (Lab of Prof. Axel Ullrich), Promoted to
Senior Research Fellow in Dec 2007 and appointed
Project Leader in Aug 2008
July 2007-2009: Adjunct assistant professor at the Department of
Pharmacy, National University of Singapore

3
Ho Han Kiat
Updated: January 2013
July 2009-present: Full-Member, Toxicology Division, Office of Life
Science, National University of Singapore
July 2009-present: Assistant professor at the Department of Pharmacy,
National University of Singapore
Jan 2011-present: Member of the Management Committee of the Drug
Development Unit at the National University of
Singapore
Mar 2011-present: Member (alternate) IACUC Review Board at the
National University of Singapore
Jul 2011-present Resident Fellow at Raffles Hall, National University
of Singapore
Jul 2012-present: Editorial Member, Signpost Open Access Journal of
Pathobiology and Toxicology
Apr 2012-April 2014 External Examiner, School and Chemical and Life
Sciences, Ngee Ann Polytechnic
Supervisory Experiences:
1. Research team leader:
Sharon Pok, Lab officer (2006-2008)
Loo Hooi Linn, Lab officer (2005-2007)
Tay Liang Seah, Senior research officer (2007-09)
Priscilla Foo, Senior research officer (2007-8)
Winnie Wong, Lab officer (2007-12)
Lim Kah Suan, Intern (2006, 2008)
Ong Hui Min (2008-2009)
Ervinna Pang (2009-10)
Teo Yi Ling, Research assistant (2011)
Chew Yun Shan, Research assistant (2011-12)
Angie Yeo, Research assistant (2011-)
Ho Jia Pei, Research assistant (2012-)
2. Final year project (FYP) supervisor:
Lim Kah Suan, NTU BSc Biological Sciences (2007-2008)
Poh Weijie, NUS BSc (Life Science) Honours (2008-09)
Oh Jing Wen, NUS BSc (Pharmacy) (2008-09)

Lee Chern Yih, NUS BSc (Pharmacy) (2009-10)
Vivian Teo, NUS BSc (Pharmacy) (2009-10)
Joanne Sng, NUS BSc (Pharmacy) (2009-10)
Debra Chan, NUS BSc (Pharmacy) (2010-11)
Tan An Gie, NUS BSc (Pharmacy) (2010-11)
Edwin Tan, NUS BSc (Pharmacy) (2010-11)
Gavin Cheah, NUS BSc (Pharmacy) (2011-12)
Jonathan Goh, NUS BSc (Pharmacy) (2011-12)
Ng Hui Wen, NUS BSc (Pharmacy) (2011-12)
Loh Kep Yong, Univ of London B(Pharm) (2012)
Hazel Chia, NUS BSc (Pharmacy) (2012-13)
Vivien Tham, NUS BSc (Pharmacy) (2012-13)
Wee Hui Ling, NUS BSc (Pharmacy) (2012-13)
3. PhD supervisor:
Phua Lee Cheng (2009-)
Duan Yan (2009-11, graduated with MSc)
Pang Yi Yun (2010-)
Tan Cheau Yih (2010-)
Zhao Chun Yan (2011-)
Co-supervisor for another 3 graduate students (2007-)
4. PhD committee member:
Leow Pay Chin, Dept of Pharmacy, NUS (2008-2011)
Tian Quan, Dept of Pharmacy, NUS (2008-2010)
Liew Chin Yee, Dept of Pharmacy (2009-2011)
Amrita Nagle, Dept of Pharmacy (2010-)
Sun Lingyi, Dept of Pharmacy (2010-)
Rosita Koh, Dept of Pathology (2011-)
Ekarin Chulikorn, Dept of Biochemistry (2011-)
Jaymie Lin Siqi, Dept of Medicine (2011-)
Zhang Luqi, Dept of Pharmacy (2012-)
Training:
4
Ho Han Kiat
Updated: January 2013
May 1997-Jun 1997: Attachment at Changi General Hospital, Singapore,
as pharmacy assistant.
Jun 1999-Jul 1999: Overseas industrial internship at Glaxo Smithkline
Australia.

5
Ho Han Kiat
Updated: January 2013
Jul-Aug 2001: Industrial Internship at S*Bio Pte Ltd, a
pharmaceutical research firm in Singapore.
Jan 2007: Participant in the EMBO lab management course in
Heidelberg, Germany
June 2007: Participant in an A*STAR organized Team
Effectiveness Course
Jan 2008: Participant at the Performance Management
Programme (SDC Consulting)
April 2009: Participant at the Mid-American Toxicology Course
in Kansas City, MO, USA
Aug 2009-Dec 2011: Completed Professional Development Programme
(Teaching) at CDTL, NUS.
Invited Speaker:
Jun 1999: Speaker at the 4 th South East Asian Pharmaceutical
Students’ Society Congress at Cebu, The Philippines.
Title: Public Awareness of Diabetes Mellitus in
Singapore.
Jun 2004: Invited speaker for a research seminar at the
Genome Institute of Singapore. Title: Mechanisms of
tetrafluoroethylcysteine cytotoxicity.
Jun 2004: Invited speaker for a research seminar at the 2 nd
Annual Merck Graduate Student Symposium at West
Point, PA, USA. Title: Mechanisms of
tetrafluoroethylcysteine cytotoxicity.
Jan 2006: Invited speaker at the 2 nd AAPS-NUS Student
Chapter Symposium. Title: An investigation of cellular
responses to tetrafluoroethylcysteine-induced
mitochondrial dysfunction.
Apr 2006: Invited speaker at the General Surgery Research
Conference at Tan Tock Seng Hospital. Title: Drug-

6
Ho Han Kiat
Updated: January 2013
induced hepatotoxicity and hepatocellular carcinoma:
A basic science approach
May 2007: Oral presentation of research project at Schloss
Ringberg, Germany. Title: SOG project extension:
Exploring the role of tyrosine kinases in hepatocellular
carcinoma
Oct 2007: Invited speaker for AAPS-NUS student chapter
workshop. Title: Back to the future with toxicological
sciences: Impact on the art of pharmacy
Nov 2007: Invited speaker for the A*STAR Young Scientist
Workshop on Cancer. Title: The involvement of
FGFR4 on hepatocellular carcinoma
May 2008: Speaker for IMB seminar series. Title: FGFR4 in
hepatocellular carcinoma: An emerging target for a
surging disease.
Nov 2008: Invited speaker for 1 st HCC Workshop by Singapore
Institute of Clinical Sciences/Singapore Immunology
Network. Title: The role of FGFR4 in hepatocellular
carcinoma.
Jan 2009: Faculty Lecture at Department of Pharmacy, NUS.
Title: Tyrosine kinase inhibitors in HCC: An over-rated
regimen or under-developed rudiment?
Jun 2009: Invited speaker at Max-Planck Institute for
Biochemistry Annual Symposium at Schloss
Ringberg, Germany. Title: Tyrosine kinase inhibitors
in HCC: An over-rated regimen or under-developed
rudiment?
Jul 2009: Invited speaker at the Singapore Pharmacy
Congress 2010. Title: Drug development and
toxicology.
Mar 2010: Invited speaker at the 3 rd Pep-Con 2010 at Beijing,
China. Title: Exploring FGFR4 as a potential target for
the treatment of hepatocellular carcinoma.
Apr 2010: Invited speaker at Faculty Teaching Workshop,
NUS. Title: Incorporating research into teaching: A
case study.

7
Ho Han Kiat
Updated: January 2013
Apr 2010: Invited speaker at the 6 th AAPS-NUS Student
Chapter Scientific Symposium. Title: Laboratory of
liver cancer and drug-induced liver toxicity research.
May 2010: Invited speaker at the NUS-AAPS
PharmSci@Vietnam 2010, Ho Chi Minh City
Symposium, Vietnam. Title: Exploring multi-kinase
targeting inhibitors for the treatment of hepatocellular
carcinoma.
May 2010: Invited speaker at the NUS-AAPS
PharmSci@Shanghai 2010, Fudan University, China.
Title: Exploring multi-kinase targeting inhibitors for the
treatment of hepatocellular carcinoma.
Jun 2010: Invited speaker at the 3 rd World Cancer Congress in
Singapore. Title: Exploring multi-kinase targeting
inhibitors for the treatment of hepatocellular
carcinoma.
Sep 2010: Invited speaker at the NUS Pharmacy Medicinal
Chemistry Symposium. Title: Phenotype-based
screening approach to uncover new multi-targeting
kinase inhibitors
Jun 2011: Invited speaker and session chair at the
International Conference on Materials for Advanced
Technologies 2011, Singapore. Title: Extrapolating
safety assessment methods from drug discovery to
nanomaterials: Opportunities and pitfalls.
Jul 2011: Invited speaker at the Max-Planck Institute for
Biochemistry. Title: Benzylidine-indolinones as
therapeutics against against hepatocellular
carcinoma: Kinase inhibitors and beyond.
Jul 2011: Invited speaker at Vichem Corporation. Title: An
overview of structure toxicity relationship: Implications
on drug design.
Jan 2012: Invited speaker at the Pharmacy Teaching
Workshop: Stimulating learning with applicationbased
assessments.

8
Ho Han Kiat
Updated: January 2013
May 2012: Invited speaker at Vichem Corporation. Title:
Development of novel FGFR4 inhibitor
Jan 2012: Invited facilitator for microteaching session at the
CDTL training for teaching assistants.
July 2012: Invited speaker at the CDTL workshop series:
Motivating students using a student-centric approach
Sep 2012: Invited speaker at the SG-GCP course by NHG R&D
Office: Introduction to Drug Development Process
Sep 2012: Speaker at the 8 th Congress in Toxicology for
Developing Countries, Bangkok, Thailand. Title:
Understanding the mechanism of lapatinib-induced
hepatotoxicity: An in vitro-in vivo investigation
Nov 2012: Invited speaker at CDTL Postgraduate Seminar
Series. Title: Components of a Research Paper
Nov 2012: Invited speaker at School of Design and
Environment, NUS. Title: Engaging students through
application-based assessments.
Feb 2013: Invited speaker at Asia Pacific Association for the
Study of the Liver (APASL) Annual Meeting,
Singapore. Title: Exploring the use of mesenchymal
stem cell-derived exosomes in drug-induced liver
injury.
Invited reviewer:
Journals:
1. Am J Pathology (1)
2. Biochemical Pharmacology (21)
3. BMC Cancer (1)
4. Cancer Research (1)
5. Curr Pharm Biotech (1)
6. Expert Opin Drug Metab Toxicol (1)
7. Human Immunology (1)
8. J Drug Delivery (1)
9. J Pediatric Surgery (1)
10. J Toxicology and Environmental Health Sciences (1)
11. Toxicological Sciences (2)
12. African Journal of Pharmacy and Pharmacology (1)

13. Journal of Oncology Pharmacy Practice (1)
14. Biomatters (1)
15. Materials Letters (1)
16. Biotechnology Advances (1)
17. J Biotechnology (1)
Publications (Posters/Abstracts)
9
Ho Han Kiat
Updated: January 2013
1. Hu ZH, Ho HK, Bammler TK, Kavanagh TJ, Fausto N, Nelson SD, Bruschi
SA. Toxicologist 66, LB66 (2002). Genomic responses to specific
intramitochondrial damage.
2. Ho HK, Hu ZH, Tzung, SP, Hockenbery DM, Fausto N, Nelson SD,
Bruschi SA. Toxicologist 72, Abstract 1558 (2003). Inhibition of BAX
translocation and necrosis with BCL-xL overexpression in a well
characterized cell culture model for tetrafluoroethylcysteine-induced
nephrotoxicity.
3. Ho HK, Jia YK, Hu ZH, Hockenbery DM, Fausto N, Nelson SD, Bruschi
SA. Toxicologist 78, Abstract 253 (2004). Heat shock protein responses in
tetrafluoroethylcysteine-induced cytotoxicity.
4. Ho HK, White CC, Fernandez C, Kavanagh TJ, Fausto N, Nelson SD,
Bruschi SA. Toxicologist 82, Abstract 813 (2005). Nrf2 activation involves
an oxidative-stress independent pathway in tetrafluoroethylcysteineinduced
cytotoxicity.
5. Ho HK, Pok S, Ruhe JE, Streit SS, Hart S, Foo P, Loo HL, Aung MO,
Ullrich A, Lim SG. Molecular Targets and Cancer Therapeutics, Abstract
C73 (2007). Exploring the involvement of FGFR4 in hepatocellular
carcinoma.
6. Ho HK, Pok S, Streit SS, Ruhe JE, Hart S, Loo HL, Lim KS, Aung MO,
Lim SG, Ullrich A. Liver Growth, Development and Disease, Abstract 15
(2008). FGFR4 Regulates Proliferation, Anti-apoptosis and Alphafetoprotein
Secretion During Hepatocellular Carcinoma Progression and
Represents a Potential Target for Therapeutic Intervention
7. Foo P, Ho HK, Streit S, Ruhe JE, Hart S, Ullrich A. Molecular Targets and
Cancer Therapetuics, Abstract 361 (2008). FGFR4 Y367C: Contributes to
a constitutively active FGFR4 and tumor aggressiveness in breast cancer
cell line.

10
Ho Han Kiat
Updated: January 2013
8. Ho HK, Wong W, Lim KS, Zhang W, Go ML, Ullrich A. Biopharma Asia
Convention (2010). Benzylidine-indolinones are effective multi-targeted
kinase inhibitor therapeutics against hepatocellular carcinoma.
9. Chan CYE, Oh JW, New LS, Ho HK. 3rd Asia Pacific Regional ISSX
Meeting (2009), Drug Metabolism Reviews, 41, S2:89. Investigating the
molecular mechanism of lapatinib-induced liver toxicity.
10. Saha S, New LS, Ho HK, Chui WK, Chan CYE. 3rd Asia Pacific Regional
ISSX Meeting 2009, Drug Metabolism Reviews, 41, S2:26. Investigation of
the role of thiazolidinedione of troglitazone in inducing hepatotoxicity in
humans.
11. Duan Y, Wong W, Poh W, Chua BT, Ho HK. Asia Pacific Association for
the Study of Liver Annual Meeting 2011. Overexpression of Tyro3 and the
implications on HCC progression.
12. Tan CY, Lai RC, Lin SQ, Dan YY, Lim SK, Ho HK. Asia Pacific
Association for the Study of Liver Annual Meeting 2011. Exploring
mesenchymal stem cell derived exosome as a hepatoprotective agent for
the treatment of drug-induced liver injury.
13. Pang YY, Go ML, Ho HK. Toxicologist 126, Abstract 342 (2012). A
structure-toxicity-relationship investigation of 2-phenylamino-phenylacetic
acid analogs
14. Phua LC, Koh PK, Cheah PY, Yip LY, Sampathkumar A, Tan YM, Ho HK,
Chan ECY. 12th European International Society for the Study of
Xenobiotics Meeting. Global gas chromatography/time-of-flight mass
spectrometry (GC/TOFMS)-based metabotyping of lyophilized human
feces.
15. Phua LC, Mainak M, Cheah PY, Koh PK, Ho HK, Chan ECY. 2013
Gastrointestinal Cancers Symposium, San Francisco, CA, USA. Global
profiling of fecal and tissue miRNAs in Asian Chinese colorectal cancer
patients.
16. Tan CY, Lai RC, Lin SQ, Dan YY, Lim SK, Ho HK. International Society for
the Study of Xenobiotics Annual Meeting, Dallas, TX, USA. Exploring
mesenchymal stem cell derived exosome as a hepatoprotective agent in
drug-induced acute liver injury.
Publications (Research papers)

11
Ho Han Kiat
Updated: January 2013
1. Wee HL, Ho HK, Li SC. Singapore Med J, 43, 128-34 (2002). Public
awareness of diabetes mellitus in Singapore.
2. Ho HK (Corresponding author), Hu ZH, Tzung SP, Hockenbery DM,
Fausto N, Nelson SD, Bruschi, SA. Biochemical Pharmacology, 69, 147-
157 (2005). BCL-xL overexpression effectively protects against
tetrafluoroethylcysteine-induced intramitochondrial damage and cell death.
3. Ho HK (Corresponding author), White CC, Fernandez C, Kavanagh TJ,
Fausto N, Nelson SD, Bruschi SA. Toxicological Sciences, 86, 354-364
(2005). Nrf2 activation involves an oxidative-stress independent pathway
in tetrafluoroethylcysteine-induced cytotoxicity.
4. Ho HK, Jia YK, Coe KJ, Gao Q, Doneanu CE, Hu ZH, Bammler TK, Beyer
RP, Fausto N, Bruschi SA, Nelson SD. Biochemical Pharmacology, 72,
80-90 (2006). Cytosolic heat shock proteins and heme oxygenase-1 are
preferentially induced in response to specific and localized
intramitochondrial damage by tetrafluoroethylcysteine.
5. Boelsterli UA, Ho HK, Zhou SF, Leow KY. Current Drug Metabolism, 7,
715-727 (2006). Bioactivation and hepatotoxicity of nitroaromatic drugs.
6. Coe, KJ, Jia Y, Ho HK, Rademacher P, Bammler TK, Beyer RP, Farin FM,
Woodke L, Plymate SR, Fausto N, Nelson SD. Chem Res Tox, 20, 1277-
1290 (2007). Comparison of the cytotoxicity of the nitroaromatic drug
flutamide to its cyano analog in the hepatocyte cell line TAMH: Evidence
for complex I inhibition and mitochondrial dysfunction using toxicogenomic
screening.
7. Ruhe JE, Streit SS, Hart S, Wong CH, Specht K, Knyazev P, Knyazeva K,
Tay LS, Loo HL, Foo P, Wong W, Pok S, Lim SJ, Ong HM, Luo M, Ho HK,
Peng K, Lee TC, Bezler M, Mann C, Gaertner S, Hoefler H, Iacobelli S,
Peter S, Tay A, Brenner S, Venkatesh B, Ullrich A. Cancer Res, 67,
11368-11376 (2007). Genetic alterations in the tyrosine kinase
transcriptome of human cancer cell lines.
8. Ho HK (Corresponding author), Pok S, Streit SS, Ruhe JE, Hart S, Loo
HL, Lim KS, Aung MO, Lim SG, Ullrich A. J Hepatology, 50, 118-127
(2009). FGFR4 Regulates Proliferation, Anti-apoptosis and Alphafetoprotein
Secretion During Hepatocellular Carcinoma Progression and
Represents a Potential Target for Therapeutic Intervention.
9. Saha S, New LS, Ho HK, Chui WK, Chan ECY. Tox Letters, 192, 141-149
(2010). Investigation of the role of thiazolidinedinone ring of troglitazone in
inducing hepatotoxicity

12
Ho Han Kiat
Updated: January 2013
10. Roidl A, Foo P, Mann C, Bechtold S, Berger HJ, Streit S, Ruhe JE, Hart S,
Ullrich A, Ho HK (Corresponding author). Oncogene, 29, 1543-1552
(2010). The FGFR4 Y367C Mutant is a Dominant Oncogene in MDA-
MD453 Breast Cancer Cells.
11. Saha S, New LS, Ho HK, Chui WK, Chan ECY. Tox Letters, 195(2-3),
135-141 (2010). Direct toxicity effects of sulfo-conjugated troglitazone on
human hepatocytes.
12. Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK and Chan
CYE. Mol Pharmacol, 78, 693-703 (2010). Mechanism-based inactivation
of Cytochrome P450 3A4 by lapatinib.
13. Nayak T, Li J, Phua LC, Ho HK, Ren Y, Pastorin G. ACS Nano, 4(12),
7717-25 (2010). Thin films of functionalized multi-walled carbon
nanotubes as suitable scaffold materials for stem cells proliferation and
bone formation.
14. Chan CY, New LS, Ho HK, Chan EC. Tox Letters, 206(3), 314-24 (2011).
Reversible time-dependent inhibition of CYP450 enzymes by duloxetine
and the inertness of its thiophen ring towards bioactivation.
15. Teo YL, Saetaew M, Chanthawong S, Yap YS, Chan EC, HO HK, Chan A.
Breast Cancer Res Treat, 133(2), 703-711 (2012). Effect of CYP3A4
inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro
evidence.
16. Poh W, Wong W, Ong H, Aung MO, Lim SG, Chua BT, Ho HK
(Corresponding author). Mol Cancer, 11:14 (2012). Klotho-beta
overexpression as a novel target for suppressing proliferation and
fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
17. Chan EC, New LS, Chua TB, Yap CW, Ho HK, Nelson SD. Drug Metab
Disp, 40(7), 1414-1422 (2012). Interaction of lapatinib with cytochrome
P450 3A5.
18. Tian Q, Wong W, Xu Y, Chan Y, Ho HK, Pastorin G, Ang WH. Chem
Comm, 48(44), 5467-5469 (2012). Immobilisation of quantum dots by bioorthogonal
PCR amplification and labeling for direct gene detection and
quantification.
19. Chng HT, Ho HK, Yap CW, Lam SH, Chan EC. J Biomol Screen, 17(7),
974-986 (2012). An investigation of the bioactivation potential and
metabolism profile of zebrafish versus human.

13
Ho Han Kiat
Updated: January 2013
20. Zhao C, Tan A, Pastorin G, Ho HK. Biotech Adv, E published (2012).
Nanomaterial scaffolds for stem cell differentiation and proliferation in
tissue engineering.
21. Saha S, Chan DS, Lee CY, Wong W, Yap CW, Chui WK, Chan EC, Ho
HK. Eur J Pharmacol 697(1-3), 13-23 (2012). Pyrrolidinediones reduce the
toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer
properties.
22. Teo YL, Ho HK, Chan A. Cancer Treat Rev 39(2), 199-206 (2013). Risk of
tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A
meta-analysis.
23. Phua LC, Mal M, Koh PK, Cheah PY, Chan EC, Ho HK. Cancer
Chemother Pharmacol E-published (2012). Investigating the role of
nucleoside transporters in the resistance of colorectal cancer to 5fluorouracil
therapy.
24. Chan A, Ho HK, Cheung YT, Teo YL. Adv Pharmacoepidem Drug Safety,
1:5 (2012). Supportive care in cancer patients: Current challenges and
opportunities.
Patents
1. PCT International Application No. PCT/SG2007/000412 for the invention
entitled, “Cancer-Related Protein Kinases”
2. PCT International Application No. PCT/SG2009/000376 for invention
entitled, “A Novel Benzylidene-indolinone (Compound 47) as a Multitargeted
Tyrosine Kinase Inhibitor with Potent Anti-cancer Properties
Against Liver Cancer”
3. US Provisional Application number 61/514,950 “Benzylidene-indolinone
and their medical uses”.
Research Grants
1. Faculty of Science, Start-up Grant: “Exploring the role of receptor tyrosine
kinase Tyro3 in Hepatocellular Carcinoma”, Sep 2009-Aug 2012,
$180,000 (Role: PI)
2. NMRC New Investigator Grant: “Exploring Mesenchymal Stem Cellderived
Conditioned Medium as Hepatoprotective Agents Against Druginduced
Liver Injuries”, Nov 2009-Nov 2011, $170,000 (Role: PI)

14
Ho Han Kiat
Updated: January 2013
3. Faculty of Science, FRC Grant: “Molecular profiling of fecal microRNAs for
the detection of colorectal cancer”, May 2010-Apr 2013, $175,000 (Role:
PI)
4. A*STAR TSRP Integrated Nano-photo-bio interface grant: “Quantum dotbased
microfluidic device for determining etiology of rhinitis”. May 2010-
Apr 2013, $902,510 (Role: Co-PI)
5. A*STAR-SSCC grant: “Systematic characterization of the intrinsic drug
metabolizing capacity of hepatocytes differentiated from stem cells”, Sep
2010-Aug 2013, $243,783 (Role: Co-PI)
6. A*STAR-NKTH Grant, “Development of Small Molecule Inhibitors of
FGFR4 and ACK1”, Sep 2009-Aug 2012, $530,000 (Role: Collaborator)
7. Singapore Cancer Society Cancer Research Grant, “Optimization of a
Dosage Regimen for sunitinib in metastatic renal cell carcinoma treatment
through pharmacokinetic monitoring to achieve better efficacy and safety
profile”, Jan 2011-Jan 2012, $99,700 (Role: Collaborator)